167 related articles for article (PubMed ID: 7750122)
1. Interleukin-6 involvement in mesothelioma pathobiology: inhibition by interferon alpha immunotherapy.
Bielefeldt-Ohmann H; Marzo AL; Himbeck RP; Jarnicki AG; Robinson BW; Fitzpatrick DR
Cancer Immunol Immunother; 1995 Apr; 40(4):241-50. PubMed ID: 7750122
[TBL] [Abstract][Full Text] [Related]
2. Interferon-alpha and -gamma in combination with chemotherapeutic drugs: in vitro sensitivity studies in four human mesothelioma cell lines.
Hand AM; Husgafvel-Pursiainen K; Pelin K; Vallas M; Suitiala T; Ekman A; Mattson M; Mattson K; Linnainmaa K
Anticancer Drugs; 1992 Dec; 3(6):687-94. PubMed ID: 1288739
[TBL] [Abstract][Full Text] [Related]
3. Epigenetic modulation enhances the therapeutic effect of anti-IL-13R(alpha)2 antibody in human mesothelioma xenografts.
Takenouchi M; Hirai S; Sakuragi N; Yagita H; Hamada H; Kato K
Clin Cancer Res; 2011 May; 17(9):2819-29. PubMed ID: 21357681
[TBL] [Abstract][Full Text] [Related]
4. Potential for interferon-alpha-based therapy in mesothelioma: assessment in a murine model.
Bielefeldt-Ohmann H; Fitzpatrick DR; Marzo AL; Jarnicki AG; Musk AW; Robinson BW
J Interferon Cytokine Res; 1995 Mar; 15(3):213-23. PubMed ID: 7584666
[TBL] [Abstract][Full Text] [Related]
5. Intrapleural production of interleukin 6 during mesothelioma and its modulation by gamma-interferon treatment.
Monti G; Jaurand MC; Monnet I; Chretien P; Saint-Etienne L; Zeng L; Portier A; Devillier P; Galanaud P; Bignon J
Cancer Res; 1994 Aug; 54(16):4419-23. PubMed ID: 8044791
[TBL] [Abstract][Full Text] [Related]
6. Chemo-adoptive immunotherapy of nude mice implanted with human colorectal carcinoma and melanoma cell lines.
Gazit Z; Weiss DW; Shouval D; Yechezkeli M; Schirrmacher V; Notter M; Walter J; Kedar E
Cancer Immunol Immunother; 1992; 35(2):135-44. PubMed ID: 1596937
[TBL] [Abstract][Full Text] [Related]
7. Interferon-alpha induces the expression of the L-selectin homing receptor in human B lymphoid cells.
Evans SS; Collea RP; Appenheimer MM; Gollnick SO
J Cell Biol; 1993 Dec; 123(6 Pt 2):1889-98. PubMed ID: 7506267
[TBL] [Abstract][Full Text] [Related]
8. Interferon (IFN)-alpha and IFN-gamma in combination with methotrexate: in vitro sensitivity studies in four human mesothelioma cell lines.
Hand A; Pelin K; Mattson K; Linnainmaa K
Anticancer Drugs; 1995 Feb; 6(1):77-82. PubMed ID: 7756687
[TBL] [Abstract][Full Text] [Related]
9. The role of interleukin-1beta and platelet-derived growth factor-AB in antifibrosis mediated by native human interferon alpha.
Santak G; Santak M; Forcić D
Surgery; 2010 Sep; 148(3):490-8. PubMed ID: 20176391
[TBL] [Abstract][Full Text] [Related]
10. Malignant mesothelioma: the antiproliferative effect of cytokine combinations on three human mesothelioma cell lines.
Hand AM; Husgafvel-Pursiainen K; Tammilehto L; Mattson K; Linnainmaa K
Cancer Lett; 1991 Jul; 58(3):205-10. PubMed ID: 1906777
[TBL] [Abstract][Full Text] [Related]
11. Interleukin-6 induces both cell growth and VEGF production in malignant mesotheliomas.
Adachi Y; Aoki C; Yoshio-Hoshino N; Takayama K; Curiel DT; Nishimoto N
Int J Cancer; 2006 Sep; 119(6):1303-11. PubMed ID: 16642474
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of an attenuated vesicular stomatitis virus vector expressing interferon-beta for use in malignant pleural mesothelioma: heterogeneity in interferon responsiveness defines potential efficacy.
Saloura V; Wang LC; Fridlender ZG; Sun J; Cheng G; Kapoor V; Sterman DH; Harty RN; Okumura A; Barber GN; Vile RG; Federspiel MJ; Russell SJ; Litzky L; Albelda SM
Hum Gene Ther; 2010 Jan; 21(1):51-64. PubMed ID: 19715403
[TBL] [Abstract][Full Text] [Related]
13. Differential responsiveness of human and rat mesothelioma cell lines to recombinant interferon-gamma.
Phan-Bich L; Buard A; Petit JF; Zeng L; Tenu JP; Chretien P; Monnet I; Boutin C; Bignon J; Lemaire G; Jaurand MC
Am J Respir Cell Mol Biol; 1997 Feb; 16(2):178-86. PubMed ID: 9032125
[TBL] [Abstract][Full Text] [Related]
14. Interaction between dactinomycin and tumor necrosis factor in mesothelioma. Cachexia without oncolysis.
Bowman RV; Whitaker D; Manning LS; Davis MR; Robinson BW
Cancer; 1991 May; 67(10):2495-500. PubMed ID: 2015549
[TBL] [Abstract][Full Text] [Related]
15. Synergistic interactions of interleukin 1, interferon-beta, and tumor necrosis factor in terminally differentiating a mouse myeloid leukemic cell line (M1). Evidence that interferon-beta is an autocrine differentiating factor.
Onozaki K; Urawa H; Tamatani T; Iwamura Y; Hashimoto T; Baba T; Suzuki H; Yamada M; Yamamoto S; Oppenheim JJ
J Immunol; 1988 Jan; 140(1):112-9. PubMed ID: 3275716
[TBL] [Abstract][Full Text] [Related]
16. Cytokine gene therapy of mesothelioma. Immune and antitumor effects of transfected interleukin-12.
Caminschi I; Venetsanakos E; Leong CC; Garlepp MJ; Robinson BW; Scott B
Am J Respir Cell Mol Biol; 1999 Sep; 21(3):347-56. PubMed ID: 10460752
[TBL] [Abstract][Full Text] [Related]
17. Recombinant human interferon-alpha A/D enhances the expression of Ly-6A/E, Ly-6C, and TAP antigens on murine T lymphocytes.
Dumont FJ
J Interferon Res; 1988 Jun; 8(3):347-56. PubMed ID: 2842413
[TBL] [Abstract][Full Text] [Related]
18. HLA antigen expression and malignant mesothelioma.
Christmas TI; Manning LS; Davis MR; Robinson BW; Garlepp MJ
Am J Respir Cell Mol Biol; 1991 Sep; 5(3):213-20. PubMed ID: 1910807
[TBL] [Abstract][Full Text] [Related]
19. Effect of recombinant human interferon-alpha in vitro and in vivo on mitogen-induced lymphocyte blastogenesis in cats.
Weiss RC; Oostrom-Ram T
Vet Immunol Immunopathol; 1990 Feb; 24(2):147-57. PubMed ID: 2139993
[TBL] [Abstract][Full Text] [Related]
20. Native human IFN-alpha is a more potent suppressor of HDF response to profibrotic stimuli than recombinant human IFN-alpha.
Santak G; Santak M; Forcić D
J Interferon Cytokine Res; 2007 Jun; 27(6):481-90. PubMed ID: 17572012
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
